Literature DB >> 26352731

Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes.

Sarah Tansley1, Lucy R Wedderburn.   

Abstract

PURPOSE OF REVIEW: To explore the different characteristics of the serological phenotypes identified in juvenile and adult myositis, consider how differences between the two groups might be explained and discuss how this enhances our understanding of disease pathogenesis. RECENT
FINDINGS: Current research has focussed on two main areas: first, defining the autoantibody associated disease phenotype in greater detail, particularly with regard to cutaneous disease and within specified populations such as juvenile-onset disease and different ethnic groups, and second, we have gained new insights into disease pathogenesis through studies analysing genetic associations and autoantigen expression.
SUMMARY: Although there are many clinically important differences between adult and juvenile-onset myositis, recent work has highlighted many of the similarities at least within autoantibody-defined subgroups. Viewing age at disease onset as a continuum with its own influence on disease phenotype strengthens the ability of autoantibodies to define homogenous disease groups, and may be important in understanding the relationship between autoantibodies and disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26352731     DOI: 10.1097/BOR.0000000000000224

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  10 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 2.  Enhancing translational research in paediatric rheumatology through standardization.

Authors:  Rae S M Yeung; Salvatore Albani; Brian M Feldman; Elizabeth Mellins; Berent Prakken; Lucy R Wedderburn
Journal:  Nat Rev Rheumatol       Date:  2016-09-22       Impact factor: 20.543

Review 3.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

Review 4.  Treatment of Calcinosis in Juvenile Dermatomyositis.

Authors:  Ovgu Kul Cinar; Charalampia Papadopoulou; Clarissa A Pilkington
Journal:  Curr Rheumatol Rep       Date:  2021-02-08       Impact factor: 4.592

Review 5.  Treatment of Juvenile Dermatomyositis: An Update.

Authors:  Charalampia Papadopoulou; Lucy R Wedderburn
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

6.  Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.

Authors:  Sarah L Tansley; Stefania Simou; Gavin Shaddick; Zoe E Betteridge; Beverley Almeida; Harsha Gunawardena; Wendy Thomson; Michael W Beresford; Angela Midgley; Francesco Muntoni; Lucy R Wedderburn; Neil J McHugh
Journal:  J Autoimmun       Date:  2017-06-26       Impact factor: 7.094

7.  The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.

Authors:  Alexander Oldroyd; Jamie C Sergeant; Paul New; Neil J McHugh; Zoe Betteridge; Janine A Lamb; William E Ollier; Robert G Cooper; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

8.  Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis.

Authors:  Claire T Deakin; John Bowes; Lisa G Rider; Frederick W Miller; Lauren M Pachman; Helga Sanner; Kelly Rouster-Stevens; Gulnara Mamyrova; Rodolfo Curiel; Brian M Feldman; Adam M Huber; Ann M Reed; Heinrike Schmeling; Charlotte G Cook; Lucy R Marshall; Meredyth G Ll Wilkinson; Stephen Eyre; Soumya Raychaudhuri; Lucy R Wedderburn
Journal:  Hum Mol Genet       Date:  2022-07-21       Impact factor: 5.121

Review 9.  The Vasculopathy of Juvenile Dermatomyositis.

Authors:  Charalampia Papadopoulou; Liza J McCann
Journal:  Front Pediatr       Date:  2018-10-09       Impact factor: 3.418

10.  Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.

Authors:  S Soponkanaporn; C T Deakin; P W Schutz; L R Marshall; S A Yasin; C M Johnson; E Sag; S L Tansley; N J McHugh; L R Wedderburn; T S Jacques
Journal:  Neuropathol Appl Neurobiol       Date:  2018-06-04       Impact factor: 8.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.